Evidence map›Paper›PMID 26136154›Full record

ArticleScientific reports2015

QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.

Yuan-Yuan Chen, Quan Li, Chun-Shui Pan, Li Yan, Jing-Yu Fan, Ke He, Kai Sun, Yu-Ying Liu, Qing-Fang Chen, Yan Bai and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Review
  3. International journal of molecular sciences · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  16. Article
  17. Experimental Study on the Effect ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  18. Review
  19. Article
  20. Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Yuan-Yuan Chen1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Quan Li1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Chun-Shui Pan1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Li Yan1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Jing-Yu Fan1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Ke He1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Kai Sun1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Yu-Ying Liu1] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [2] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [3] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Qing-Fang Chen1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Yan BaiInstitute of Vascular Medicine, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptide, Ministry of Health, Beijing, China.
Chuan-She Wang1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Bing HeThe School of Chinese Medicine of Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.
Ai-Ping LvThe School of Chinese Medicine of Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.
Jing-Yan Han1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.
Peking University · CNHong Kong Baptist University · HKPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to explore the holistic mechanism for the antihypertrophic effect of a compound in Chinese medicine, QiShenYiQi Pills (QSYQ) and the contributions of its components to the effect in rats with cardiac hypertrophy (CH). After induction of CH by ascending aortic stenosis, rats were treated with QSYQ, each identified active ingredient (astragaloside IV, 3, 4-dihydroxy-phenyl lactic acid or notoginsenoside R1) from its 3 major herb components or dalbergia odorifera, either alone or combinations, for 1 month. QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry. Proteomic analysis and western blot showed that the majority of differentially expressed proteins in the heart of QSYQ-treated rats were associated with energy metabolism or oxidative stress. Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated. In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.

Indexed as

AnimalsCardiomegalyDrugs, Chinese HerbalEnergy MetabolismGene Expression RegulationGinsenosidesHeartMyocardiumOxidative StressPressureProteomicsRatsRats, Sprague-DawleySaponinsTriterpenesastragaloside ADrugs, Chinese HerbalGinsenosidesnotoginsenoside R1SaponinsTriterpenes

Identifiers

PMID26136154
PMCPMC4488877
OpenAlexW2258959318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.